Cormorant Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cormorant Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-75,000	Closed	-$5.08M	–	76
2017 Q1	$5.08M	Sell	75,000 -35,842	-32%	-$2.73M	0.74%	42
2016 Q4	$7.79M	Hold	110,842	–	–	1.05%	29
2016 Q3	$7.86M	Hold	110,842	–	–	0.87%	39
2016 Q2	$5.42M	Buy	110,842 +1,342	+1%	+$86.8K	0.77%	41
2016 Q1	$6.93M	Hold	109,500	–	–	1.04%	33
2015 Q4	$12.3M	Hold	109,500	–	–	1.47%	27
2015 Q3	$10.5M	Buy	109,500 +7,500	+7%	+$859K	1.68%	20
2015 Q2	$10.4M	Hold	102,000	–	–	1.39%	23
2015 Q1	$6.33M	Sell	102,000 -18,000	-15%	-$1,000K	0.98%	32
2014 Q4	$5.27M	Hold	120,000	–	–	0.81%	34
2014 Q3	$6.79M	Hold	120,000	–	–	1.4%	19
2014 Q2	$5.39M	Buy	120,000 +60,000	+100%	+$2.47M	1.43%	27
2014 Q1	$2.93M	Buy	+60,000	New	+$3.09M	0.67%	43

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cormorant Asset Management's RARE Position: Q2 2017 in Review

Cormorant Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2017, closing a stake of 75,000 shares — an estimated $5.08M sold.

Cormorant Asset Management first reported a position in RARE in Q1 2014 and held it in 13 quarters. The position peaked at $12.3M in Q4 2015. 158 funds tracked by Wall St. Rank hold RARE as of Q2 2017.

Cormorant Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2017 after selling out during the quarter.
Cormorant Asset Management sold 75,000 Ultragenyx Pharmaceutical shares in Q2 2017, an estimated $5.08M.
Cormorant Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 13 quarters.
Cormorant Asset Management's Ultragenyx Pharmaceutical position peaked at $12.3M in Q4 2015.
158 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2017.

Based on Cormorant Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.